Webinar
Mature Chamber Specific Human Cardiomyocytes for High Throughput Cardiotoxicity Testing
Todd Herron (University of Michigan) and Anne Sheldrake (StemBioSys)
Webinar
Todd Herron (University of Michigan) and Anne Sheldrake (StemBioSys)
Dr. Todd Herron is a faculty member at the University of Michigan and is Director of the Frankel Cardiovascular Regeneration Core Laboratory. His laboratory has made advances in the maturation of hiPSC-CMs and creating high throughput screening for electrophysiology functional analysis. The laboratory derives new patient specific hiPSC lines and routinely differentiates stem cells to the cardiac lineage. The Herron lab uses these cells to study the mechanisms of inherited cardiomyopathies like hypertrophic cardiomyopathy. In other studies the Herron lab has developed in vitro models of more common cardiomyopathies like ischemic cardiomyopathy that occurs secondary to atherosclerosis (clogged arteries). We aim to utilize hiPSC-CMs to uncover mechanisms of heart disease, to repair failing hearts, and to discover new medicines to treat heart failure. In newer avenues of regenerative medicine, the Herron lab has also started to generate hiPSC derived pancreatic tissue and 3D islets for diabetes research and for the development of regenerative pancreas therapies to cure diabetes.
Anne Sheldrake is Principal Scientist at StemBioSys. In her current role, she manages manufacturing, quality control, and research and development of StemBioSys’ portfolio of products, including primary and iPSC-derived cells and cell-derived extracellular matrices. She has been working on applications of CELLvoTM matrix, StemBioSys’ core technology, for seven years. She is passionate about identifying new applications of cell-derived extracellular matrices and working with collaborators to develop improvements to traditional cell culture methods. In her prior role at the Texas Biomedical Research Institute, she worked to identify circulating miRNA biomarkers of bone mineral density in a cohort of baboons. Ms. Sheldrake received her M.S. in biomedical engineering from the University of Texas at San Antonio and B.S. in chemical engineering with honors in bioengineering from the Schreyer Honors College at Pennsylvania State University.
On the REPROCELL blog
Latest in Clinical Capabilities
Discover the differentiation potential of induced pluripotent stem cells (iPSC) to cytotoxic NK cells, including recent advancements in research and therapy.
16 October 2024
What you should know about the FDA’s Biological License Application Process
Learn about the FDA's Biological License Application process, including submission requirements, review phases, and expedited pathways for biologics approvals.
19 September 2024
Nucleic Acid Extraction in Clinical Research
REPROCELL is revolutionizing drug discovery in clinical research through nucleic acid extraction.
08 August 2024
Data Privacy and Protection in AI for Precision Medicine
Discover how AI is revolutionizing data protection and security in precision medicine.
31 October 2023
Bias in AI for precision medicine
Without proper and due consideration in the design and delivery of new therapies and diagnostics, there is a risk that biased datasets will skew outcomes towards certain groups.
02 October 2023